| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 243 | 280 | 294 | 345 | 331 | 376 | 390 | 443 | 518 | 589 | 666 | 782 |
| Expenses | 228 | 256 | 266 | 306 | 297 | 316 | 319 | 354 | 410 | 454 | 494 | 528 |
| EBITDA | 15 | 24 | 28 | 39 | 34 | 60 | 71 | 89 | 108 | 135 | 172 | 254 |
| Operating Profit % | 6 % | 8 % | 9 % | 11 % | 10 % | 16 % | 18 % | 20 % | 20 % | 22 % | 24 % | 20 % |
| Depreciation | 11 | 10 | 11 | 14 | 15 | 16 | 17 | 16 | 16 | 17 | 21 | 21 |
| Interest | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 1 | 0 | 0 | 1 | 1 |
| Profit Before Tax | 1 | 12 | 15 | 20 | 15 | 37 | 54 | 73 | 92 | 118 | 233 | 232 |
| Tax | 0 | 0 | 3 | 7 | 4 | 7 | 14 | 22 | 24 | 30 | 50 | 49 |
| Net Profit | 1 | 12 | 12 | 14 | 11 | 29 | 40 | 52 | 68 | 88 | 183 | 183 |
| EPS in ₹ | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.01 | 110.80 | 110.50 |
RPG Life Sciences
RPG Life Sciences
2,245.00
-246.80
(-9.90%)
Q1 Quarterly Results are out. Check out the updated financials2 days ago
View
Market Cap
3,713.01 Cr
EPS
110.80
PE Ratio
35.51
Dividend Yield
0.97 %
Industry
Healthcare52 Week High
2,974.95
52 Week Low
1,834.75
PB Ratio
7.74
Debt to Equity
0.00
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
RPG Life Sciences Targets ₹500 Crore OTC Market with ₹200 Crore Investment in Immunosuppressants
3 days ago
3 days agoRPG Life Sciences has announced its strategic plans to target the ₹500 crore over-the-counter (OTC) pharmaceutical market. The company plans to invest ₹200 crore specifically in immunosuppressant drugs. Additionally, RPG Life Sciences is focusing on global generics as part of its long-term growth strategy.
RPG Life's co-executive has confirmed the company's strategic focus on strengthening its international formulations and API (Active Pharmaceutical Ingredient) business. The expansion strategy involves attracting new clients, entering new markets, and introducing new molecules to provide broader treatment options.
RPG Life Sciences appointed Deepak Shukla as Chief Executive - API Business effective July 28, 2025. Shukla brings 25 years of experience from companies including UPL Group, Teva Group, and Dr. Reddy's Laboratories. The company reported quarterly results for the period ended June 30, 2025, showing revenue from operations of ₹168.9 crores compared to ₹165.4 crores in the same quarter last year. EBITDA margin decreased to 24.1% from 25.1%, while PAT margin improved to 21.0% from 21.8%. The domestic formulations segment contributed 69% to total sales with 9.5% growth, while the API segment contributed 12% but declined 22.4% due to a fire incident in one manufacturing block. International formulations contributed 19% with a 2.7% decline. The Board also approved revisions to the policy for determination of materiality of events.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,702.20 | #1 4,08,414.80 | 35.57 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 55.97 | |
6,584.00 | 1,74,784.51 | 80.22 | 9,712.00 | 0.89 | 2,191 | 23.05 | 40.37 | |
1,572.00 | 1,26,971.67 | 22.93 | 28,409.50 | 7.12 | 5,291 | 9.88 | 70.77 | |
3,622.90 | 1,21,969.00 | 63.65 | 11,539.40 | 6.99 | 1,911 | 19.91 | 72.46 | |
1,287.40 | 1,07,442.68 | #1 18.77 | 33,741.20 | 16.73 | 5,725 | 1.26 | 54.50 | |
2,541.60 | 1,04,899.14 | 61.83 | 12,744.20 | 19.57 | 2,007 | -10.91 | 52.39 | |
980.10 | 98,620.99 | 21.15 | 23,511.00 | 13.82 | 4,615 | -0.19 | 54.96 | |
1,960.50 | 89,535.15 | 27.44 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 53.75 | |
32,895.00 | 69,899.58 | 50.72 | 6,684.70 | 10.80 | 1,414 | 27.83 | 42.22 | |
1,127.00 | 65,456.34 | 18.86 | 31,378.10 | 17.55 | 3,366 | -0.50 | 47.15 |
Forecast
Actual
Growth Rate
Revenue Growth
13.03 %
Net Income Growth
108.89 %
Cash Flow Change
-17.49 %
ROE
47.67 %
ROCE
40.14 %
EBITDA Margin (Avg.)
12.63 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 |
| Fixed Assets | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 172 |
| Current Assets | 86 | 87 | 96 | 143 | 97 | 126 | 176 | 207 | 264 | 298 | 465 |
| Capital Work in Progress | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 91 | 127 |
| Other Assets | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 |
| Total Liabilities | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 |
| Current Liabilities | 67 | 67 | 79 | 121 | 78 | 83 | 80 | 80 | 103 | 131 | 120 |
| Non Current Liabilities | 5 | 5 | 21 | 16 | 13 | 8 | 7 | 9 | 9 | 7 | 7 |
| Total Equity | 125 | 134 | 147 | 155 | 161 | 177 | 216 | 256 | 308 | 375 | 531 |
| Reserve & Surplus | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 0 | 1 | -1 | 0 | 0 | 40 | 17 | -32 | -5 | 9 |
| Investing Activities | -10 | -15 | -30 | -16 | -19 | -11 | -8 | -35 | -106 | -79 | -42 |
| Operating Activities | -2 | 33 | 7 | 15 | 46 | 50 | 58 | 65 | 91 | 94 | 78 |
| Financing Activities | 12 | -18 | 23 | 0 | -27 | -39 | -11 | -14 | -17 | -20 | -27 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 72.07 % | 72.07 % | 72.07 % | 72.07 % | 72.07 % | 72.41 % | 72.61 % | 72.61 % | 72.81 % | 72.81 % | 72.81 % | 72.81 % | 72.81 % | 72.81 % | 72.81 % | 72.95 % | 72.95 % | 72.95 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.46 % | 0.56 % | 0.89 % | 1.14 % | 1.35 % | 1.30 % | 1.45 % | 1.35 % |
| DIIs | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 2.04 % | 2.02 % | 2.12 % | 2.29 % | 3.59 % | 3.79 % | 4.19 % | 4.63 % | 5.45 % | 6.06 % | 6.14 % | 6.48 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 20.45 % | 20.59 % | 20.58 % | 20.65 % | 20.85 % | 20.37 % | 19.91 % | 20.26 % | 19.91 % | 19.45 % | 18.41 % | 18.16 % | 17.41 % | 16.79 % | 15.92 % | 15.58 % | 15.33 % | 15.46 % |
| Others | 7.47 % | 7.33 % | 7.34 % | 7.28 % | 7.07 % | 7.21 % | 5.44 % | 5.10 % | 5.16 % | 5.45 % | 4.73 % | 4.67 % | 4.70 % | 4.62 % | 4.47 % | 4.11 % | 4.12 % | 3.76 % |
| No of Share Holders | 18,701 | 20,564 | 23,674 | 22,768 | 22,821 | 22,115 | 20,757 | 21,360 | 20,837 | 20,226 | 21,088 | 21,866 | 22,137 | 22,232 | 23,481 | 24,891 | 24,867 | 25,832 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2.8 | 2.4 | 2.4 | 4 | 7.2 | 9.6 | 12 | 16 | 24 |
| Dividend Yield (%) | 0.00 | 0.73 | 0.97 | 1.41 | 1.03 | 1.28 | 1.4 | 0.79 | 0.7 | 0.96 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 Jul 2025 |  Quarterly Result Announcement | NA | 25 Jul 2025 | 2,548.80 | 2,515.25 |
| 16 Jul 2025 |  Annual General Meeting | NA | 16 Jul 2025 | 2,341.50 | 2,557.00 |
| 27 Jun 2025 |  Dividend | ₹ 4.00 /share | 27 Jun 2025 | 2,244.30 | 2,424.10 |
| 27 Jun 2025 | Dividend | ₹ 20.00 /share | 27 Jun 2025 | 2,244.30 | 2,424.10 |
| 28 Apr 2025 | Quarterly Result Announcement | NA | 28 Apr 2025 | 2,197.25 | 2,244.30 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 2,067.10 | 2,166.65 |
| 07 Nov 2024 | Quarterly Result Announcement | NA | 07 Nov 2024 | 2,443.95 | 2,673.90 |
| 16 Jul 2024 | Annual General Meeting | NA | 16 Jul 2024 | 1,535.60 | 1,640.55 |
| 28 Jun 2024 | Dividend | ₹ 16.00 /share | 28 Jun 2024 | 1,560.55 | 1,599.95 |
| 21 Jul 2023 | Dividend | ₹ 12.00 /share | 21 Jul 2023 | 820.55 | 996.65 |
| 15 Jul 2022 | Dividend | ₹ 9.60 /share | 14 Jul 2022 | 589.35 | 568.55 |
| 17 Aug 2021 | Dividend | ₹ 7.20 /share | 13 Aug 2021 | 490.80 | 516.85 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication2 days ago
2 days agoAmendment In Policy Of The Company3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Change in Management3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
3 days agoUnaudited Financial Result For The Quarter Ended On June 30 20253 days ago
3 days agoBoard Meeting Outcome for Outcome Of The Board Meeting Held On July 25 20253 days ago
3 days agoBoard Meeting Intimation for Board Meeting Intimation To Consider And Approve Unaudited Financial Results For The Quarter Ended June 30 202510 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication10 days ago
10 days agoVoting Result Of 18Th Annual General MeetingJul 16, 2025
Jul 16, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 16, 2025
Jul 16, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 16, 2025
Jul 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025 Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The CompanyJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 24, 2025
Jun 24, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 23, 2025
Jun 23, 2025Reg. 34 (1) Annual Report.Jun 23, 2025
Jun 23, 2025Notice Of 18Th Annual General Meeting Scheduled On Wednesday July 16 2025.Jun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 16, 2025
Jun 16, 2025Intimation Of Record Date For 18Th AGM Of The Company Scheduled On July 16 2025.
Jun 14, 2025
Jun 14, 2025 Email Communication To Shareholders Regarding Dividend Taxation ProvisionsJun 05, 2025
Jun 05, 2025Further To Our Letter Dated April 28 2025 We Enclose Herewith Updated Annexure C Pursuant To Details Required As Per SEBI Circular No. SEBI/HO/CFD/CFD-Pod-1/P/CIR/2023/123 Dated July 132023.Jun 03, 2025
Jun 03, 2025Intimation To Shareholders Holding Shares In Physical Mode Regarding Furnishing Of PAN KYC Details And NominationJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJun 02, 2025
Jun 02, 2025In Accordance With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations") To Shareholders Whose Shares Are Liable To Be Transferred To IEPF Authority.Jun 01, 2025
Jun 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 29, 2025
May 29, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 05, 2025
May 05, 2025Earning Call Audio Recording Link For Q$ Ended On March 31 2025.Apr 29, 2025
Apr 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 29, 2025
Apr 29, 2025Announcement under Regulation 30 (LODR)-Investor PresentationApr 29, 2025
Apr 29, 2025Amendment Of PoliciesApr 28, 2025
Apr 28, 2025Disclosure Under 30(5) Of SEBI (Listing Obligations And Disclosure Requirement) Regulations 2015Apr 28, 2025
Apr 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 28, 2025
Apr 28, 2025Corporate Action-Board approves DividendApr 28, 2025
Apr 28, 2025Appointment Of Secretarial Auditor For Term Of Five (5) YearsApr 28, 2025
Apr 28, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateApr 28, 2025
Apr 28, 2025Financial Result For Quarter And Year Ended On March 31 2025Apr 28, 2025
Apr 28, 2025Board Meeting Outcome for Audited Financial Result For Quarter And Year Ended On March 31 2025Apr 28, 2025
Apr 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 23, 2025
Apr 23, 2025Board Meeting Intimation for Pursuant To Regulation 29 Of The SEBI LODR 2015 This Is To Inform You That A Meeting Of The Board Of Directors Of The Company Is Scheduled On Monday April 28 2025Apr 21, 2025
Apr 21, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 19, 2025
Apr 19, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 08, 2025
Apr 08, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Mar 21, 2025
Mar 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 25, 2025
Feb 25, 2025Update On Transfer Of Surplus Vacant Leasehold LandFeb 13, 2025
Feb 13, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations
And Disclosure Requirements) Regulations 2015Feb 07, 2025
Feb 07, 2025Technical Indicators
RSI(14)
Neutral 35.62
ATR(14)
Volatile 114.53
STOCH(9,6)
Neutral 34.65
STOCH RSI(14)
Oversold 2.71
MACD(12,26)
Bearish -33.35
ADX(14)
Strong Trend 35.33
UO(9)
Bearish 37.80
ROC(12)
Downtrend And Accelerating -11.08
WillR(14)
Oversold -96.21
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Mirae Asset Multicap Fund Direct - Growth | 1.00% | -7300 | 0.02% | -0.09% | |
 Motilal Oswal Quant Fund Direct-Growth | 0.00% | -3534 | -0.54% | -0.86% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.08% | 1 | 0.01% | 0.01% | |
 Quant Healthcare Fund Direct - Growth | 8.78% | 0 | 0.91% | 0.83% | |
| Quant Multi Cap Fund Direct-Growth | 0.43% | 0 | 0.04% | 0.05% | |
 Union Small Cap Fund Direct-Growth | 0.82% | 0 | 0.05% | 0.03% | |
 WhiteOak Capital Pharma and Healthcare Fund Direct - Growth | 1.13% | 0 | 0.04% | 0.34% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
